ModernMedicine Resource Center More Topics

Hot Topics in Prostate Cancer

Are you seeing more advanced prostate Ca in your practice?Three urologists give their take on the frequency of patients presenting with prostate cancer.
The return of prostate cancer: A step backwardUrologist Henry Rosevear, MD discusses his thoughts on PSA screening and the recent increase in patients presenting with metastatic disease.
Early-stage PCa incidence drops post-USPSTFThe authors of a recent research letter reported a 6% drop in incidence rates for early-stage prostate cancer in men 50 years of age and older from 2012 to 2013.
What influences opting out of active surveillance?A recent study suggests that a man’s race/ethnicity might influence decisions about undergoing treatment and re-biopsies.
Prostate Ca: Novel model predicts ‘true cancer state’Although various calculators are available for predicting biopsy results in men with prostate cancer being managed by active surveillance, a novel model developed by researchers at Johns Hopkins University is unique for its ability to predict a patient’s “true cancer state”; ie, the Gleason score that would be assigned on whole-gland analysis after radical prostatectomy.
Slow breathing technique helps reduce hot flashesA slow breathing technique guided by an iOS application was able to reduce the occurrence of vasomotor symptoms in a small study of prostate cancer survivors treated with androgen deprivation therapy.
QoL prognostic in mCRPC patients on salvage therapyClinical outcomes of men with metastatic castration-resistant prostate cancer treated with enzalutamide (XTANDI) after chemotherapy correlate with health-related quality of life both at treatment initiation and its change longitudinally, researchers reported at the American Society of Clinical Oncology annual meeting in Chicago.
Negative mpMRI does not rule out significant PCaAs interest in using multiparametric MRI as a diagnostic tool for prostate cancer increases, urologists should know that a negative mpMRI does not rule out significant prostate cancer, researchers advised at the AUA annual meeting in San Diego.